Efficacy and safety of donafenib plus transarterial chemoembolization and immunotherapy for hepatocellular carcinoma

Table 2 Incidence of adverse events in the patients following treatment, n (%)

AEs	Any grade No.	Grade 1 No. (%)	Grade 2 No. (%)	Grade 3 No. (%)	Grade 4 No. (%)	Grade 5 No. (%)
Palmar-plantar erythrodysesthesia	17 (56.7)	7	8	2	0	0
Rash	12 (40)	5	5	2	0	0
Diarrhea	5 (16.7)	0	2	0	1	0
Hypertension	4 (13.3)	3	1	0	0	0
Hair loss	4 (13.3)	2	2	1	0	0
Fatigue	2 (6.7)	0	1	1	0	0
Gastrointestinal hemorrhage	1 (3.33)	0	0	1	0	0

AE: Adverse events.